FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCEN PERPENT AND TRADEMARK OF COMMERCEN PERPENT PE				ATTY DOCKET NO. 01997.033600.4		APPLICATION NO. 09/714,792		
LIST	OF REFER	AND TRADEMARK ENCES CITED BY veral sheets if nece	APPLICANT(S)	Mary Collins et al.				
(250 december 31 depts in rec			SEP 1 3 2004	FILING DATE November 16, 2000		GROUP 1647		
			TO TO TO THE MAN	U.S. PATENT DOCUMENTS				
'EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS	S SUBCLASS	FILING DATE	
		<u>-</u>						
	·			·				
						-		
				· · · · · · · · · · · · · · · · · · ·				
-				FOREIGN PATENT DOCUMENTS			TRANSLATION	
·		DOCUMENT NUMBER	DATE	COUNTRY	CLAS	SUBCLASS	YES/NO/ OR ABSTRACT	
				· .				
	_					<u> </u>		
		·						
			<u> </u>					
<u> </u>				(S) (Including Author, Title, Date, Pertinent Pages,				
FH		Husain, et al., "Interleukin-13 Receptor as a Unique Target for Anti-Glioblastoma Therapy", Int. J. Cancer, Vol. 92 (2001), pages 168-175						
FH	1	Barth, "hIL-13 PE38QQR NeoPharm", Current Opinion in Investigational Drugs, Vol. 2, No. 9 (2001), pages 1309-1313						
FH	1	Li, et al., "Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice", Protein Engineering, Vol. 15, No. 5 (2002), pages 419-427						
FH	!	Husain, et al., "Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside", <i>Journal of Neuro-Oncology</i> , Vol. 65 (2003), pages 37-48						
FH	1	Mintz, et al., "Molecular targeting with recombinant cytotoxins of interleukin-13 receptor α2-expressing glioma", <i>Journal of Neuro-Oncology</i> , Vol. 64 (2003), pages 117-123						
EXAMINER	fich		m d	DATE CONSIDERED	3010]		

Sheet 1 of 1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.